NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Editas Medicine, Inc. EDIT
12 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 40.5M
Revenue, FY2025 · full 12-year series below
Revenue $M
Net income $M
FY2025 · Revenue 40.5 · Net income -160.1
Compound annual growth
Revenue compounded at −14.9% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−395 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -394.9% · Net -395.0%
ROE
FY2025 · ROE -198.1%
Each USD of equity lost 198 cents this year.
The 12-year record
12 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | · | · |
| Operating income $B | −0.2 | −0.3 | −0.2 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| EBITDA $B | −0.2 | −0.2 | −0.2 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · |
| Net income $B | −0.2 | −0.2 | −0.2 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 |
| Free cash flow $B | −0.2 | −0.2 | −0.1 | −0.2 | −0.2 | −0.2 | −0.0 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 |
| EPS, diluted $ | −1.80 | −2.88 | −2.02 | −3.21 | −2.85 | −1.98 | −2.68 | −2.33 | −2.98 | −3.02 | −28.55 | −12.46 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −198.1 | −98.1 | −43.2 | −48.2 | −40.6 | −35.4 | −53.6 | −49.5 | −70.2 | −377.5 | · | · |
| Shares out B | 0.10 | 0.08 | 0.08 | 0.07 | 0.07 | 0.06 | 0.05 | 0.05 | 0.04 | 0.04 | 0.00 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 46 reconciliationsAUDITED
Reconciled in 12 of 19 fiscal years. 30 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2014